Finding responders with multimodal fusion of histology and clinical data

Exploring multimodal AI for personalized medicine

In the pursuit of precision medicine, identifying treatment responders remains a challenge. By integrating multiple data sources—histology, clinical information, and AI—we can enhance predictive capabilities and drive better patient outcomes.

Challenge

The client needed a reliable approach to differentiate responders from non-responders using clinical and histology data. Ensuring fair validation and optimal data utilization was a key requirement.

Approach

  • Explored multimodal AI fusion techniques.
  • Designed a rigorous validation process with extensive patient stratification.
  • Combined tissue morphology graphs, histology images, and clinical data.
  • Applied various deep learning methodologies for accurate predictions.

Results

  • Achieved over a 10% improvement in ROC AUC compared to the baseline model.
  • Identified the most predictive data modalities for response differentiation.
  • Ensured high reliability through a strict validation schema.

This AI-driven approach enables more effective patient stratification, improving treatment outcomes through precise responder identification.

Want to achieve similar efficiency gains? Let's discuss how we can optimize your clinical project.

You might be also interested in:

Foundational Models for AI in Biology
Foundational Models for AI in Biology
BioIT 2025 insights
AI, Genomics and the Future of Medicine: Highlights from Bio-IT World Conference & Expo 2025
The Scaling Paradox: Why Adding More Cloud Resources in Bioinformatics Doesn’t Always Solve the Problem
Poster: Enabling Real-Time Analytics in Clinical Trials

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!